{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Tandem Diabetes Care, Inc.
Tandem Diabetes Care Hits Day Low at $13.25 Amid Price Pressure
Tandem Diabetes Care, Inc. faced notable volatility on November 6, 2025, with a significant stock decline. Over the past week and month, the stock has continued to drop, reflecting a troubling long-term performance. Financial metrics reveal challenges, including low return on equity and high debt levels, indicating ongoing difficulties.
Tandem Diabetes Care Experiences Revision in Stock Evaluation Amid Market Fluctuations
Tandem Diabetes Care, Inc. has experienced significant stock fluctuations, with a 52-week high of $42.70 and a low of $9.98. Recent evaluations show mixed technical indicators, and the company's performance has lagged behind the S&P 500, reflecting ongoing challenges in the market.
Is Tandem Diabetes Care, Inc. technically bullish or bearish?
As of October 3, 2025, Tandem Diabetes Care, Inc. shows a mildly bearish technical trend, with mixed MACD signals and recent outperformance against the S&P 500, but significant negative long-term returns of -58.33% year-to-date and -64.07% over the past year.
Tandem Diabetes Care Stock Soars 12.2% to Intraday High of $14.85
Tandem Diabetes Care, Inc. saw a notable increase in its stock price on October 3, 2025, reflecting strong short-term performance compared to the S&P 500. However, the company faces long-term challenges, including significant declines over the past year and five years, alongside concerns regarding its financial health.
Is Tandem Diabetes Care, Inc. technically bullish or bearish?
As of October 3, 2025, Tandem Diabetes Care, Inc. shows a mildly bearish trend with mixed technical indicators, significantly underperforming the S&P 500 with returns of -63.64% over the past year and -70.92% over three years.
Is Tandem Diabetes Care, Inc. technically bullish or bearish?
As of October 3, 2025, Tandem Diabetes Care, Inc. shows a mildly bearish trend with key indicators like moving averages and Bollinger Bands reflecting this stance, while it has significantly underperformed the S&P 500 with year-to-date and one-year returns of -59.16% and -63.64%, respectively.
Is Tandem Diabetes Care, Inc. technically bullish or bearish?
As of July 8, 2025, Tandem Diabetes Care, Inc. is in a bearish trend with weak strength, showing mixed signals from technical indicators and significantly underperforming the S&P 500 with a year-to-date return of -63.24%.
Is Tandem Diabetes Care, Inc. overvalued or undervalued?
As of August 3, 2022, Tandem Diabetes Care, Inc. is considered overvalued and risky due to its negative P/E ratio, poor return metrics, and significant underperformance compared to the S&P 500, indicating operational challenges and a weaker valuation relative to peers.
Tandem Diabetes Care Hits Day High with 8.7% Surge in Stock Price
Tandem Diabetes Care, Inc. has seen a significant intraday gain, reaching USD 13.44, but the stock has struggled over the past year with a 72.7% decline. Financial metrics indicate low profitability, high debt reliance, and ongoing volatility, raising concerns about the company's market position and investor confidence.
Is Tandem Diabetes Care, Inc. overvalued or undervalued?
As of August 3, 2022, Tandem Diabetes Care, Inc. is considered overvalued and risky, with unfavorable financial ratios and a year-to-date stock performance of -43.86%, significantly underperforming the S&P 500's 2.44%.
Is Tandem Diabetes Care, Inc. technically bullish or bearish?
As of May 1, 2025, Tandem Diabetes Care, Inc. shows a mildly bearish trend due to conflicting signals from moving averages, Bollinger Bands, and MACD across different timeframes, indicating market uncertainty.
Who are in the management team of Tandem Diabetes Care, Inc.?
As of March 2022, the management team of Tandem Diabetes Care, Inc. includes Chairman Kim Blickenstaff, CEO John Sheridan, Lead Independent Director Dick Allen, and Independent Directors Rajwant Sodhi, Edward Cahill, Peyton Howell, and Kathleen McGroddy-Goetz. They oversee the company's strategic direction and operations.
What does Tandem Diabetes Care, Inc. do?
Tandem Diabetes Care, Inc. is a medical device company that designs and commercializes products for insulin-dependent diabetes. As of March 2025, it reported net sales of $234 million and a net loss of $131 million, with a market cap of approximately $1.34 billion.
How big is Tandem Diabetes Care, Inc.?
As of Jun 18, Tandem Diabetes Care, Inc. has a market capitalization of $1.34 billion, with net sales of $982.95 million and a net profit of -$183.86 million over the latest four quarters. Shareholder's funds are $263.10 million, and total assets amount to $967.66 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
